Trials (Jan 2024)

Internet-based transdiagnostic treatment for emotional disorders in Arabic- and Farsi-speaking refugees: study protocol of a randomized controlled trial

  • Johanna Boettcher,
  • Manuel Heinrich,
  • Maria Boettche,
  • Sebastian Burchert,
  • Heide Glaesmer,
  • Euphrosyne Gouzoulis-Mayfrank,
  • Carina Heeke,
  • Martina Hernek,
  • Christine Knaevelsrud,
  • Alexander Konnopka,
  • Louisa Muntendorf,
  • Hannah Nilles,
  • Laura Nohr,
  • Steffi Pohl,
  • Sophia Paskuy,
  • Isabelle Reinhardt,
  • Susan Sierau,
  • Nadine Stammel,
  • Christina Wirz,
  • Babette Renneberg,
  • Birgit Wagner

DOI
https://doi.org/10.1186/s13063-023-07845-5
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Background Refugee populations have an increased risk for mental disorders, such as depression, anxiety, and posttraumatic stress disorders. Comorbidity is common. At the same time, refugees face multiple barriers to accessing mental health treatment. Only a minority of them receive adequate help. The planned trial evaluates a low-threshold, transdiagnostic Internet-based treatment. The trial aims at establishing its efficacy and cost-effectiveness compared with no treatment. Methods N = 131 treatment-seeking Arabic- or Farsi-speaking patients, meeting diagnostic criteria for a depressive, anxiety, and/or posttraumatic stress disorder will be randomized to either the intervention or the waitlist control group. The intervention group receives an Internet-based treatment with weekly written guidance provided by Arabic- or Farsi-speaking professionals. The treatment is based on the Common Elements Treatment Approach (CETA), is tailored to the individual patient, and takes 6–16 weeks. The control group will wait for 3 months and then receive the Internet-based treatment. Discussion The planned trial will result in an estimate of the efficacy of a low-threshold and scalable treatment option for the most common mental disorders in refugees. Trial registration German Registry for Clinical Trials DRKS00024154. Registered on February 1, 2021.

Keywords